|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gray R, Hentschke R, Isaac S, Mead R,
Ozturk A, Rieley P, Smale K and Stern R: Sampling variation of
reported results. Nature. 234:230–231. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen YL, Ge GJ, Qi C, Wang H, Wang HL, Li
LY, Li GH and Xia LQ: A five-gene signature may predict sunitinib
sensitivity and serve as prognostic biomarkers for renal cell
carcinoma. J Cell Physiol. 233:6649–6660. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Escudier B, Porta C, Schmidinger M,
Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V and Horwich A: Renal
cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 27:v58–v68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lam JS, Shvarts O, Leppert JT, Pantuck AJ,
Figlin RA and Belldegrun AS: Postoperative surveillance protocol
for patients with localized and locally advanced renal cell
carcinoma based on a validated prognostic nomogram and risk group
stratification system. J Urol. 174:466–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Y, He J, Liao M, Hu M, Li W, Ouyang
H, Wang X, Ye T, Zhang Y and Ouyang L: An overview of Sirtuins as
potential therapeutic target: Structure, function and modulators.
Eur J Med Chem. 161:48–77. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haigis MC and Sinclair DA: Mammalian
sirtuins: Biological insights and disease relevance. Ann Rev
Pathol. 5:253–295. 2010. View Article : Google Scholar
|
|
8
|
Sebastián C, Zwaans BM, Silberman DM,
Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber
D, et al: The histone deacetylase SIRT6 is a tumor suppressor that
controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marquardt JU, Fischer K, Baus K, Kashyap
A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al:
Sirtuin-6-dependent genetic and epigenetic alterations are
associated with poor clinical outcome in hepatocellular carcinoma
patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang C, Yu Y, Huang Q and Tang K: SIRT6
regulates the proliferation and apoptosis of hepatocellular
carcinoma via the ERK1/2 signaling pathway. Mol Med Rep.
20:1575–1582. 2019.PubMed/NCBI
|
|
11
|
Han Z, Liu L, Liu Y and Li S: Sirtuin
SIRT6 suppresses cell proliferation through inhibition of Twist1
expression in non-small cell lung cancer. Int J Clin Exp Pathol.
7:4774–4781. 2014.PubMed/NCBI
|
|
12
|
Khongkow M, Olmos Y, Gong C, Gomes AR,
Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong
S, et al: SIRT6 modulates paclitaxel and epirubicin resistance and
survival in breast cancer. Carcinogenesis. 34:1476–1486. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qi W, Fitchev PS, Cornwell ML, Greenberg
J, Cabe M, Weber CR, Roy HK, Crawford SE and Savkovic SD: FOXO3
growth inhibition of colonic cells is dependent on intraepithelial
lipid droplet density. J Biol Chem. 288:16274–16281. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Colas E, Perez C, Cabrera S, Pedrola N,
Monge M, Castellvi J, Eyzaguirre F, Gregorio J, Ruiz A, Llaurado M,
et al: Molecular markers of endometrial carcinoma detected in
uterine aspirates. Int J Cancer. 129:2435–2444. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Xie QR, Wang B, Shao J, Zhang T,
Liu T, Huang G and Xia W: Inhibition of SIRT6 in prostate cancer
reduces cell viability and increases sensitivity to
chemotherapeutics. Protein Cell. 4:702–710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Desantis V, Lamanuzzi A and Vacca A: The
role of SIRT6 in tumors. Haematologica. 103:1–4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tao NN, Ren JH, Tang H, Ran LK, Zhou HZ,
Liu B, Huang AL and Chen J: Deacetylation of Ku70 by SIRT6
attenuates Bax-mediated apoptosis in hepatocellular carcinoma.
Biochem Biophys Res Commun. 485:713–719. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC cancer staging manual. (8th edition).
Springer International Publishing; pp. 739–747. 2017
|
|
19
|
World Medical Association: World medical
association declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kugel S, Sebastián C, Fitamant J, Ross KN,
Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, et al:
SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell.
165:1401–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ming M, Han W, Zhao B, Sundaresan NR, Deng
CX, Gupta MP and He YY: SIRT6 promotes COX-2 expression and acts as
an oncogene in skin cancer. Cancer Res. 74:5925–5933. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bauer I, Grozio A, Lasigliè D, Basile G,
Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, et al:
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine
production and migration in pancreatic cancer cells by regulating
Ca2+ responses. J Biol Chemistry. 287:40924–40937. 2012.
View Article : Google Scholar
|
|
24
|
Khongkow P, Gomes AR, Gong C, Man EP,
Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US and
Lam EW: Paclitaxel targets FOXM1 to regulate KIF20A in mitotic
catastrophe and breast cancer paclitaxel resistance. Oncogene.
35:990–1002. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prestayko AW, D'Aoust JC, Issell BF and
Crooke ST: Cisplatin (cis-diamminedichloroplatinum II).
Cancer Treat Rev. 6:17–39. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lebwohl D and Canetta R: Clinical
development of platinum complexes in cancer therapy: An historical
perspective and an update. Eur J Cancer. 34:1522–1534. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Galanski M: Recent developments in the
field of anticancer platinum complexes. Recent Pat Anticancer Drug
Discov. 1:285–295. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hueber PA, Waters P, Clark P, Clarke P,
Eccles M and Goodyer P: PAX2 inactivation enhances
cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int.
69:1139–1145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu W, Chen H, Wong N, Haynes W, Baker CM
and Wang X: Pseudohypoxia induced by miR-126 deactivation promotes
migration and therapeutic resistance in renal cell carcinoma.
Cancer Lett. 394:65–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu
J, Yao W, Yu G, An R, Chen Z, et al: Inhibition of SMYD2 suppresses
tumor progression by down-regulating microRNA-125b and attenuates
multi-drug resistance in renal cell carcinoma. Theranostics.
9:8377–8391. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai L, Lin G, Sun L, Liu Y, Huang X, Cao
C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis
and promotes metastasis of non-small cell lung cancer via the
ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Azuma Y, Yokobori T, Mogi A, Altan B,
Yajima T, Kosaka T, Onozato R, Yamaki E, Asao T, Nishiyama M and
Kuwano H: SIRT6 expression is associated with poor prognosis and
chemosensitivity in patients with non-small cell lung cancer. J
Surg Oncol. 112:231–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Strub T, Ghiraldini FG, Carcamo S, Li M,
Wroblewska A, Singh R, Goldberg MS, Hasson D, Wang Z, Gallagher SJ,
et al: SIRT6 haploinsufficiency induces BRAF melanoma cell
resistance to MAPK inhibitors via IGF signalling. Nat Commun.
9:34402018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu L, Lin X, Zheng Y and Zhou H: Silencing
of heat shock protein 27 increases the radiosensitivity of
non-small cell lung carcinoma cells. Mol Med Rep. 20:613–621.
2019.PubMed/NCBI
|
|
36
|
Chrysovergis A, Papanikolaou VS, Tsiambas
E, Ragos V, Peschos D and Kyrodimos E: Digital Analysis of BCL2
expression in laryngeal squamous cell carcinoma. Anticancer Res.
39:1253–1257. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li H, Wang H, Deng K, Han W, Hong B and
Lin W: The ratio of Bcl-2/Bim as a predictor of cisplatin response
provides a rational combination of ABT-263 with cisplatin or
radiation in small cell lung cancer. Cancer Biomark. 24:51–59.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zha H, Aimé-Sempé C, Sato T and Reed JC:
Proapoptotic protein Bax heterodimerizes with Bcl-2 and
homodimerizes with Bax via a novel domain (BH3) distinct from BH1
and BH2. J Biol Chemistry. 271:7440–7444. 1996. View Article : Google Scholar
|
|
39
|
Reed JC, Zha H, Aime-Sempe C, Takayama S
and Wang HG: Structure-function analysis of Bcl-2 family proteins.
Regulators of programmed cell death. Adv Exp Med Biol. 406:99–112.
1996. View Article : Google Scholar : PubMed/NCBI
|
